Compare TOP & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOP | CMPS |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2021 | 2020 |
| Metric | TOP | CMPS |
|---|---|---|
| Price | $11.51 | $11.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $23.75 |
| AVG Volume (30 Days) | 151.9K | ★ 2.1M |
| Earning Date | 07-07-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.25 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,723,765.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.89 | N/A |
| 52 Week Low | $1.85 | $4.88 |
| 52 Week High | $17.42 | $15.87 |
| Indicator | TOP | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 30.82 | 45.19 |
| Support Level | $3.26 | $10.68 |
| Resistance Level | $12.41 | $12.08 |
| Average True Range (ATR) | 1.43 | 0.59 |
| MACD | -0.27 | 0.13 |
| Stochastic Oscillator | 2.81 | 45.79 |
TOP Financial Group Ltd is operates as an online brokerage firm in Hong Kong specializing in the trading of local and overseas equities, futures, and options products. It conduct the futures and stock brokerage business through three trading platforms, Esunny for futures trading and Longbridge for stock trading, all of which were licensed from third parties and can be easily accessed through its application, or APP, software, and websites. The three platforms are designed for seamless, efficient, and secure trading platform. The company operates and manages its business as a single operating and reportable segment.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.